Excelligent Diagnostics offers a CLIA‑certified blood test that quantifies a panel of >20 protein and metabolic biomarkers linked to Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Using multiplexed immuno‑assay technology and proprietary machine‑learning models, the platform generates a calibrated risk score delivered via a HIPAA‑compliant SaaS dashboard with EHR (FHIR) integration, enabling early detection and longitudinal monitoring.
Funding
Funding not disclosed
Founders
Product
Problem
Early-stage neurodegenerative diseases such as Alzheimer’s and Parkinson’s are difficult to diagnose because existing methods rely on neuroimaging or cerebrospinal‑fluid analysis, which are invasive, costly, and often unavailable in routine clinical settings. Delayed detection limits the window for therapeutic intervention and reduces the effectiveness of disease‑modifying treatments.
Solution
Excelligent Diagnostics provides a blood‑based diagnostic platform that quantifies a validated panel of protein and metabolic biomarkers associated with neurodegeneration. The assay uses multiplexed immuno‑assay technology combined with machine‑learning algorithms to generate a risk score that reflects disease presence at pre‑symptomatic or early symptomatic stages. Results are delivered through a secure cloud portal that integrates with electronic health‑record (EHR) systems, enabling clinicians to incorporate the test into standard care pathways. By offering a minimally invasive, laboratory‑validated test, the platform expands access to early screening, supports timely therapeutic decisions, and facilitates longitudinal monitoring of disease progression.
Target Audience
Primary customers are neurologists, memory‑clinic specialists, and primary‑care physicians within health‑system networks seeking reliable, non‑invasive screening tools for Alzheimer’s, Parkinson’s, and related neurodegenerative disorders. The platform also serves payer organizations and clinical research groups that require scalable early‑diagnosis solutions.
Features
- Multiplexed immuno‑assay panel covering >20 validated neurodegenerative biomarkers (e.g., phosphorylated tau, neurofilament light chain, α‑synuclein)
- CLIA‑certified laboratory workflow with >95% analytical sensitivity and specificity for early‑stage disease detection
- Proprietary machine‑learning model that converts raw biomarker concentrations into a calibrated risk score with confidence intervals
- Automated result reporting via a HIPAA‑compliant SaaS dashboard, including trend visualizations and EHR (FHIR) integration
- Standardized venous blood collection kit and cold‑chain logistics to ensure sample integrity across decentralized sites
- Scalable LDT (Laboratory‑Developed Test) framework supporting high‑throughput processing for population‑level screening programs
- Regulatory‑compliant data handling with audit trails and role‑based access controls